Osteoblast/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species

Bone

Volumn 49, Issue 3, 2011, Pages 404-411

  Zhou, Hongkang ^a   Newnum, America B ^a   Martin, Joseph R ^a   Li, Ping ^b   Nelson, Mark T ^a   Moh, Akira ^b   Fu, Xin Yuan ^b   Yokota, Hiroki ^c   Li, Jiliang ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Indiana University Purdue University Indianapolis   (United States)

Author keywords

Bone formation; Mechanotransduction; Mitochondria; Osteoblast; Reactive oxidative stress; Signal transducers and activators of transcription 3

Indexed keywords

REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERALIZATION; BONE STRESS; CELL ACTIVITY; CONTROLLED STUDY; FEMALE; GROWTH RATE; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OXIDATIVE STRESS; PROTEIN DEPLETION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; ULNA;

3T3 CELLS; ANIMALS; BONE AND BONES; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MITOCHONDRIA; OSTEOBLASTS; OSTEOCYTES; OSTEOGENESIS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; STAT3 TRANSCRIPTION FACTOR; STRESS, MECHANICAL;

EID: 79960573429     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.04.020     Document Type: Article

References (52)

1. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002, 109:1139-1142.
2. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
3. Reich N.C., Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006, 6:602-612.
4. Stepkowski S.M., Chen W., Ross J.A., Nagy Z.S., Kirken R.A. STAT3: an important regulator of multiple cytokine functions. Transplantation 2008, 85:1372-1377.
5. Zhong Z., Wen Z., Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.
6. Holland S.M., DeLeo F.R., Elloumi H.Z., Hsu A.P., Uzel G., Brodsky N., et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007, 357:1608-1619.
7. Minegishi Y., Saito M., Tsuchiya S., Tsuge I., Takada H., Hara T., et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448:1058-1062.
8. Grimbacher B., Puck J.M., Holland S.M. Hyper-IgE recurrent infections syndrome. Primary immunodeficiency diseases: a molecular & cellular approach 2007, 496-504. Oxford University Press, Inc., New York City, New York. 2nd ed. H.D. Ochs, C.I.E. Smith, J.M. Puck (Eds.).
9. Jing N., Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005, 16:601-607.
10. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998, 334(Pt 2):297-314.
11. Senaldi G., Varnum B.C., Sarmiento U., Starnes C., Lile J., Scully S., et al. Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc Natl Acad Sci U S A 1999, 96:11458-11463.
12. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20.
13. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995, 86:1243-1254.
14. Hirano T., Ishihara K., Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000, 19:2548-2556.
15. Ishihara K., Hirano T. Molecular basis of the cell specificity of cytokine action. Biochim Biophys Acta 2002, 1592:281-296.
16. Takeda K., Noguchi K., Shi W., Tanaka T., Matsumoto M., Yoshida N., et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 1997, 94:3801-3804.
17. Wegrzyn J., Potla R., Chwae Y.J., Sepuri N.B., Zhang Q., Koeck T., et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:793-797.
18. Lufei C., Ma J., Huang G., Zhang T., Novotny-Diermayr V., Ong C.T., et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 2003, 22:1325-1335.
19. Hajnoczky G., Hoek J.B. Cell signaling. Mitochondrial longevity pathways. Science 2007, 315:607-609.
20. Myers M.G. Cell biology. Moonlighting in mitochondria. Science 2009, 323:723-724.
21. Reich N.C. STAT3 revs up the powerhouse. Sci Signal 2009, 2:pe61.
22. Bai X.C., Lu D., Bai J., Zheng H., Ke Z.Y., Li X.M., et al. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun 2004, 314:197-207.
23. Basu S., Michaelsson K., Olofsson H., Johansson S., Melhus H. Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun 2001, 288:275-279.
24. Cadenas E., Davies K.J. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000, 29:222-230.
25. Kasper G., Mao L., Geissler S., Draycheva A., Trippens J., Kuhnisch J., et al. Insights into mesenchymal stem cell aging: involvement of antioxidant defense and actin cytoskeleton. Stem Cells 2009, 27:1288-1297.
26. Papiha S.S., Rathod H., Briceno I., Pooley J., Datta H.K. Age related somatic mitochondrial DNA deletions in bone. J Clin Pathol 1998, 51:117-120.
27. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
28. Varanasi S.S., Francis R.M., Berger C.E., Papiha S.S., Datta H.K. Mitochondrial DNA deletion associated oxidative stress and severe male osteoporosis. Osteoporos Int 1999, 10:143-149.
29. Almeida M., Ambrogini E., Han L., Manolagas S.C., Jilka R.L. Increased lipid oxidation causes oxidative stress, increased PPAR{gamma} expression and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem 2009, 284:27438-27448.
30. Almeida M., Han L., Martin-Millan M., O'Brien C.A., Manolagas S.C. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem 2007, 282:27298-27305.
31. Mantila Roosa S.M., Liu Y., Turner C.H. Gene expression patterns in bone following mechanical loading. J Bone Miner Res 2011, 26:100-112.
32. Robinson J.A., Chatterjee-Kishore M., Yaworsky P.J., Cullen D.M., Zhao W., Li C., et al. Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem 2006, 281:31720-31728.
33. Welte T., Zhang S.S., Wang T., Zhang Z., Hesslein D.G., Yin Z., et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A 2003, 100:1879-1884.
34. Liu F., Woitge H.W., Braut A., Kronenberg M.S., Lichtler A.C., Mina M., et al. Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. Int J Dev Biol 2004, 48:645-653.
35. Li J., Liu D., Ke H.Z., Duncan R.L., Turner C.H. The P2X7 nucleotide receptor mediates skeletal mechanotransduction. J Biol Chem 2005, 280:42952-42959.
36. Mosley J.R., March B.M., Lynch J., Lanyon L.E. Strain magnitude related changes in whole bone architecture in growing rats. Bone 1997, 20:191-198.
37. Robling A.G., Turner C.H. Mechanotransduction in bone: genetic effects on mechanosensitivity in mice. Bone 2002, 31:562-569.
38. Tozum T.F., Oppenlander M.E., Koh-Paige A.J., Robins D.M., McCauley L.K. Effects of sex steroid receptor specificity in the regulation of skeletal metabolism. Calcif Tissue Int 2004, 75:60-70.
39. Plotkin L.I., Lezcano V., Thostenson J., Weinstein R.S., Manolagas S.C., Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008, 23:1712-1721.
40. Jacobs C.R., Yellowley C.E., Davis B.R., Zhou Z., Cimbala J.M., Donahue H.J. Differential effect of steady versus oscillating flow on bone cells. J Biomech 1998, 31:969-976.
41. Sundaresan M., Yu Z.X., Ferrans V.J., Sulciner D.J., Gutkind J.S., Irani K., et al. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J 1996, 318(Pt 2):379-382.
42. Burdelya L., Catlett-Falcone R., Levitzki A., Cheng F., Mora L.B., Sotomayor E., et al. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther 2002, 1:893-899.
43. Itoh S., Udagawa N., Takahashi N., Yoshitake F., Narita H., Ebisu S., et al. A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation. Bone 2006, 39:505-512.
44. Yoshida K., Taga T., Saito M., Suematsu S., Kumanogoh A., Tanaka T., et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A 1996, 93:407-411.
45. Kawasaki K., Gao Y.H., Yokose S., Kaji Y., Nakamura T., Suda T., et al. Osteoclasts are present in gp130-deficient mice. Endocrinology 1997, 138:4959-4965.
46. Shin H.I., Divieti P., Sims N.A., Kobayashi T., Miao D., Karaplis A.C., et al. Gp130-mediated signaling is necessary for normal osteoblastic function in vivo and in vitro. Endocrinology 2004, 145:1376-1385.
47. Bellido T., Stahl N., Farruggella T.J., Borba V., Yancopoulos G.D., Manolagas S.C. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J Clin Invest 1996, 97:431-437.
48. Sanchez C., Gabay O., Salvat C., Henrotin Y.E., Berenbaum F. Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts. Osteoarthritis Cartilage 2009, 17:473-481.
49. Kido S., Kuriwaka-Kido R., Imamura T., Ito Y., Inoue D., Matsumoto T. Mechanical stress induces Interleukin-11 expression to stimulate osteoblast differentiation. Bone 2009, 45:1125-1132.
50. Li X., Placencio V., Iturregui J.M., Uwamariya C., Sharif-Afshar A.R., Koyama T., et al. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 2008, 27:7118-7130.
51. Zhou H., Mak W., Zheng Y., Dunstan C.R., Seibel M.J. Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. J Biol Chem 2008, 283:1936-1945.
52. Katoh M. Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int J Mol Med 2009, 23:763-769.